lab_safety_rep_rap_eval_etiq_06_2014-eng.xls

First Page		Document Content
Date: 2014-07-18 14:38:25 GlaxoSmithKline Fixed dose combination Lamivudine Organofluorides ViiV Healthcare Abacavir/lamivudine/zidovudine Pfizer Ondansetron Novartis Chemistry Organic chemistry Pharmacology		lab_safety_rep_rap_eval_etiq_06_2014-eng.xls Add to Reading List Source URL: www.hc-sc.gc.ca Download Document from Source Website File Size: 61,44 KB Share Document on Facebook

	Aquis Exchange Monthly Statistics May-2016 € 6,758,607,,245,455 Novartis AG DocID: 1xVO3 - View Document
	Aquis Exchange Monthly Statistics Dec-2015 € 4,614,167,,256,050 Novartis AG DocID: 1xVKG - View Document
	Aquis Exchange Monthly Statistics Apr-2016 € 7,708,388,,903,457 Novartis AG DocID: 1xTdg - View Document
	PDF Document DocID: 1xJ9t - View Document
	PDF Document DocID: 1xzSc - View Document